In a powerful display of the state’s dominance in the biotech and pharmaceutical sectors, the HealthCare Institute of New Jersey (HINJ) hosted its landmark forum, “Pulse 2026: Saving Lives Globally, Driving Our Economy Locally,” recently at Middlesex College.
The event brought together a high-powered coalition of policymakers, patient advocates, and industry titans to discuss New Jersey’s dual role as a global lifesaver and a local economic powerhouse.
Gov. Mikie Sherrill delivered the keynote address, reinforcing New Jersey’s historical and future claim to the title of “Medicine Chest of the World.”
“From the band-aid to immunotherapies, New Jersey is leading the world in curing diseases,” Sherrill told the audience. “Our life sciences companies invest billions of dollars… to discover new, cutting-edge treatments that save patients’ lives across the country and the globe, all while serving as the engine powering New Jersey’s workforce.”
Sherrill emphasized her administration’s commitment to fostering a “breakneck pace” of innovation, aiming to cement the state’s reputation by boosting high-paying jobs and supporting the R&D infrastructure that defines the Garden State.
Chrissy Buteas, president and CEO of HINJ, highlighted the sheer scale of the industry in New Jersey. The state currently boasts:
- 2,400 life science firms.
- A world-class workforce that serves as a global leader in medical advancement.
- A collaborative innovation ecosystem involving academic and research institutions.
“We are proud to partner with Governor Sherrill to strengthen our innovation ecosystem and preserve New Jersey’s global leadership,” Buteas noted, highlighting that the work done in NJ labs directly translates to cures for patients everywhere.
The forum featured two panel discussions that bridged the gap between scientific research and human impact.
Emily Meyers, executive director of the Arthritis Foundation’s NJ Chapter, spoke on the accelerating role of AI-driven advances in medicine. She stressed that while technology is moving faster than ever, the partnership between drug developers and patient advocacy groups remains the most critical component in directing research toward meaningful outcomes.
Representing the broader business community, Michele Siekerka, president & CEO of the New Jersey Business & Industry Association (NJBIA), issued a call to action for legislators.
“To maintain that leadership, it is essential that federal and state policymakers pursue smart, forward-looking policies that encourage research, investment, and innovation,” Siekerka stated, identifying the life sciences sector as the “backbone” of the state’s economy.
As Pulse 2026 concluded, the consensus among speakers was clear: New Jersey’s success is not just a matter of local pride, but a global necessity. By aligning policy with innovation, the state aims to remain the premier hub for the next generation of medical breakthroughs.
